Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06834230 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Dotinurad in Hyperuricemia With Hypertension

Study acronym: DIANA-NEXT
StatusRecruiting
PhasePhase 4
Started2025-03-28
View on ClinicalTrials.gov ↗
The effect of dotinurad on CAVI (cardio-ankle vascular index) will be compared with that of febuxostat in patients with hyperuricemia complicated by hypertension.

Amendment record

Amended 5 times since 2025-02-18; most recent filed 2025-12-07. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2025-12-07
Amendment Study Status, Outcome Measures v5
2025-11-25
Amendment Study Status, Oversight, Contacts/Locations v4
2025-06-24
Amendment Study Identification, Study Status v3
2025-03-11
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
2025-02-18
Amendment Study Identification, Study Status, Oversight v1
2025-02-18
Original filing
Trial Details
NCT Number NCT06834230
Lead Sponsor Saga University
Conditions Hyperuricemia or Gout, Hypertension
Enrollment 360 participants
Start Date 2025-03-28
Primary Completion 2027-07-31 (estimated)
Study Completion 2030-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-15